Guangdong Hengrui Pharmaceutical Co., Ltd

This study is testing whether an experimental injection called SHR-2173 can help control IgA nephropathy, a kidney disease where protein leaks into the urine. About 84 adults with the disease will receive either the real injection or a placebo (dummy shot) for 48 weeks to see if …

This study is testing an investigational injection called SHR-1819 to see if it can safely reduce the severe skin rash and intense itching of eczema in teenagers. About 200 teens, aged 12-17, whose eczema hasn't improved enough with standard creams will receive either the real in…

This study is testing an investigational injection called SHR-1139 in adults with pyoderma gangrenosum, a painful condition causing severe skin ulcers. The main goal is to see if the treatment can completely close these ulcers and keep them closed. Researchers will also monitor s…

This study is testing an investigational injection called SHR-2173 to see if it can reduce disease activity in adults with active systemic lupus erythematosus (SLE). About 245 participants will be randomly assigned to receive either the drug or a placebo for nearly a year, and re…

This early-stage study aims to understand how a new drug called HRS-9813 interacts with two existing pulmonary fibrosis medications (pirfenidone and nintedanib) in healthy volunteers. Researchers will measure how the drugs affect each other's levels in the body and monitor for si…

This early-stage study aims to understand how different injection devices affect how the body absorbs SHR-1819, a potential treatment for atopic dermatitis (eczema). Researchers will enroll 160 healthy volunteers to compare the drug's absorption and safety when delivered through …